HUP0501113A2 - Cripto blocking antibodies and uses thereof - Google Patents

Cripto blocking antibodies and uses thereof

Info

Publication number
HUP0501113A2
HUP0501113A2 HU0501113A HUP0501113A HUP0501113A2 HU P0501113 A2 HUP0501113 A2 HU P0501113A2 HU 0501113 A HU0501113 A HU 0501113A HU P0501113 A HUP0501113 A HU P0501113A HU P0501113 A2 HUP0501113 A2 HU P0501113A2
Authority
HU
Hungary
Prior art keywords
blocking antibodies
cripto blocking
cripto
antibodies
blocking
Prior art date
Application number
HU0501113A
Other languages
English (en)
Inventor
Michele Sanicola-Nadel
Kevin P Williams
Susan Schiffer
Paul Rayhorn
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27501437&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0501113(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of HUP0501113A2 publication Critical patent/HUP0501113A2/hu
Publication of HUP0501113A3 publication Critical patent/HUP0501113A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HU0501113A 2001-04-26 2002-04-17 Cripto blocking antibodies and uses thereof HUP0501113A3 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28678201P 2001-04-26 2001-04-26
US29302001P 2001-05-17 2001-05-17
US30109101P 2001-06-26 2001-06-26
US36700202P 2002-03-22 2002-03-22
PCT/US2002/011950 WO2002088170A2 (en) 2001-04-26 2002-04-17 Cripto blocking antibodies and uses thereof

Publications (2)

Publication Number Publication Date
HUP0501113A2 true HUP0501113A2 (en) 2007-05-02
HUP0501113A3 HUP0501113A3 (en) 2007-12-28

Family

ID=27501437

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0501113A HUP0501113A3 (en) 2001-04-26 2002-04-17 Cripto blocking antibodies and uses thereof

Country Status (34)

Country Link
US (6) US7531174B2 (hu)
EP (3) EP1974749B1 (hu)
JP (4) JP4307845B2 (hu)
KR (1) KR100592357B1 (hu)
CN (1) CN100352501C (hu)
AR (3) AR037223A1 (hu)
AT (2) ATE533508T1 (hu)
BG (1) BG108363A (hu)
BR (1) BR0209254A (hu)
CA (2) CA2443840C (hu)
CL (1) CL2009002199A1 (hu)
CY (1) CY1108960T1 (hu)
CZ (1) CZ20033208A3 (hu)
DE (1) DE60230868D1 (hu)
DK (1) DK1390389T3 (hu)
EA (1) EA007469B1 (hu)
EE (1) EE200300528A (hu)
ES (1) ES2321065T3 (hu)
GE (1) GEP20074091B (hu)
HK (1) HK1058935A1 (hu)
HU (1) HUP0501113A3 (hu)
IS (1) IS2662B (hu)
MX (1) MXPA03009797A (hu)
MY (2) MY150237A (hu)
NO (1) NO20034805L (hu)
NZ (1) NZ566268A (hu)
PL (1) PL207087B1 (hu)
PT (1) PT1390389E (hu)
RS (2) RS20110024A (hu)
SG (1) SG157951A1 (hu)
SI (1) SI1390389T1 (hu)
SK (1) SK14432003A3 (hu)
TR (1) TR200301846T2 (hu)
WO (1) WO2002088170A2 (hu)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR395801A0 (en) 2001-03-26 2001-04-26 Austin Research Institute, The Antibodies against cancer
US20090123470A1 (en) * 2001-03-26 2009-05-14 The Macfarlane Burnet Istitute For Medical Research And Public Health Ltd. Antibodies Against Cancer
GEP20074091B (en) * 2001-04-26 2007-04-25 Biogen Idec Inc Cripto blocking antibodies and uses thereof
US7582299B2 (en) 2001-04-26 2009-09-01 Biogen Idec Ma Inc. Cripto-specific antibodies
JP2005520566A (ja) * 2002-03-22 2005-07-14 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｃｒｉｐｔｏ特異的抗体
AU2004252170B2 (en) 2003-06-27 2011-01-27 Biogen Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
ATE437950T1 (de) * 2003-09-15 2009-08-15 Res Dev Foundation Cripto-antagonismus von activin und tgf-b signalisierung
EP3120861B1 (en) 2003-11-06 2018-08-15 Seattle Genetics, Inc. Intermediate for conjugate preparation comprising auristatin derivatives and a linker
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
CN102973947A (zh) 2004-06-01 2013-03-20 健泰科生物技术公司 抗体-药物偶联物和方法
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
CA2580141C (en) 2004-09-23 2013-12-10 Genentech, Inc. Cysteine engineered antibodies and conjugates
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
SG173313A1 (en) * 2005-01-05 2011-08-29 Biogen Idec Inc Cripto binding molecules
JP5693004B2 (ja) * 2006-07-28 2015-04-01 チルドレンズ メモリアル ホスピタル ヒト胚性幹細胞の微小環境を使用して腫瘍細胞の悪性度を抑制する方法
EP2162152A2 (en) * 2007-06-01 2010-03-17 Biogen Idec MA, Inc. Cripto binding molecules
JP2011522224A (ja) * 2008-04-21 2011-07-28 メルク・シャープ・エンド・ドーム・コーポレイション 膵ベータ細胞質量生物マーカー
EP2350131B1 (en) * 2008-11-07 2017-06-07 Research Development Foundation Compositions and methods for the inhibition of cripto/grp78 complex formation and signaling
CA2809819A1 (en) 2009-09-09 2011-03-17 Centrose, Llc Extracellular targeted drug conjugates
BR112012026213B1 (pt) 2010-04-15 2021-12-28 Medimmune Limited Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa
AU2011265054B2 (en) 2010-06-08 2016-09-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
EP2640727B1 (en) 2010-11-17 2015-05-13 Genentech, Inc. Alaninyl maytansinol antibody conjugates
AU2012228100B2 (en) 2011-03-17 2016-09-08 The University Of Birmingham Re-directed immunotherapy
KR20140122649A (ko) 2011-04-21 2014-10-20 시애틀 지네틱스, 인크. 신규 결합제-약물 콘주게이트 (ADCs) 및 그의 용도
MX2013013054A (es) 2011-05-12 2014-02-20 Genentech Inc Metodo de monitoreo de lc-ms/ms de reaccion multiple para detectar anticuerpos terapeuticos en muestras de animales utilizando peptidos de firma de estructura.
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
CN103987407B (zh) 2011-10-14 2016-08-24 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其偶联物
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
PL2906298T3 (pl) 2012-10-12 2019-04-30 Adc Therapeutics Sa Koniugaty pirolobenzodiazepina - przeciwciało
NZ707490A (en) 2012-10-12 2018-09-28 Adc Therapeutics Sa Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
ES2660029T3 (es) 2012-10-12 2018-03-20 Medimmune Limited Conjugados de anticuerpo-pirrolobenzodiazepinas
WO2014057114A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
PT2906296T (pt) 2012-10-12 2018-06-01 Medimmune Ltd Conjugados de pirrolobenzodiazepina-anticorpo
AU2013328580B2 (en) 2012-10-12 2016-01-21 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
CA2887894C (en) 2012-10-12 2019-10-29 Adc Therapeutics Sarl Pyrrolobenzodiazepine - anti-psma antibody conjugates
ES2658888T5 (es) 2012-12-21 2021-10-19 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas
AU2013366490B9 (en) 2012-12-21 2018-02-01 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
TWI680766B (zh) 2013-03-13 2020-01-01 英商梅迪繆思有限公司 吡咯并苯并二氮呯及其共軛物
MX364330B (es) 2013-03-13 2019-04-23 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
WO2014140174A1 (en) 2013-03-13 2014-09-18 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
EP3033111B1 (en) 2013-08-12 2019-03-13 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP3054986B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP3054983B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP3054985B1 (en) 2013-10-11 2018-12-26 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
PE20161394A1 (es) 2013-12-16 2017-01-06 Genentech Inc Compuestos peptidomimeticos y sus conjugados de anticuerpo-farmaco
WO2015095223A2 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
BR112016013258A2 (pt) 2013-12-16 2018-01-16 Genentech Inc composto conjugado anticorpo-droga, composição farmacêutica, método para tratar câncer e kit
CA2934617A1 (en) 2013-12-23 2015-07-02 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) with kinesin spindle protein (ksp)
JP6531166B2 (ja) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
WO2016040825A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
SG11201701128YA (en) 2014-09-12 2017-03-30 Genentech Inc Cysteine engineered antibodies and conjugates
SG11201702079UA (en) 2014-09-17 2017-04-27 Genentech Inc Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
MX2017006770A (es) 2014-11-25 2018-02-09 Adc Therapeutics Sa Conjugados de pirrolobenzodiazepina y anticuerpo.
JP6752204B2 (ja) 2014-12-03 2020-09-09 ジェネンテック， インコーポレイテッド 四級アミン化合物及びその抗体−薬物コンジュゲート
CA2980611A1 (en) * 2015-04-07 2016-10-13 Paranta Biosciences Limited A method of treating neoplasias
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
BR112017027813A2 (pt) 2015-06-22 2018-08-28 Bayer Pharma Aktiengesellschaft conjugados de agente de ligação-droga (adcs) e conjugados de agente de ligação-pró-droga (apdcs) tendo grupos enzimaticamente cliváveis
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017162663A1 (de) 2016-03-24 2017-09-28 Bayer Pharma Aktiengesellschaft Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen
US20170315132A1 (en) 2016-03-25 2017-11-02 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EP3458101B1 (en) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
WO2017205741A1 (en) 2016-05-27 2017-11-30 Genentech, Inc. Bioanalytical method for the characterization of site-specific antibody-drug conjugates
EP3464280B1 (en) 2016-06-06 2021-10-06 F. Hoffmann-La Roche AG Silvestrol antibody-drug conjugates and methods of use
CN109310781A (zh) 2016-06-15 2019-02-05 拜耳制药股份公司 具有ksp抑制剂和抗-cd123-抗体的特异性抗体-药物-缀合物(adc)
JP7093767B2 (ja) 2016-08-11 2022-06-30 ジェネンテック， インコーポレイテッド ピロロベンゾジアゼピンプロドラッグ及びその抗体コンジュゲート
EP3522933B1 (en) 2016-10-05 2021-12-15 F. Hoffmann-La Roche AG Methods for preparing antibody drug conjugates
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
JP7030811B2 (ja) 2016-12-21 2022-03-07 バイエル・ファルマ・アクティエンゲゼルシャフト Ｋｓｐ阻害剤を有する特異的抗体－薬物コンジュゲート（ａｄｃ）
CN110312533B (zh) 2016-12-21 2023-11-03 拜耳公司 具有酶促可裂解的基团的细胞毒性活性剂的前药
JP7066714B2 (ja) 2016-12-21 2022-05-13 バイエル・ファルマ・アクティエンゲゼルシャフト 酵素的に切断可能な基を有する抗体薬物コンジュゲート（ａｄｃ）
DK3544636T3 (da) 2017-02-08 2021-05-10 Adc Therapeutics Sa Pyrrolobenzodiazepin-antistof-konjugater
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
CN110582505B (zh) 2017-04-18 2021-04-02 免疫医疗有限公司 吡咯并苯并二氮杂*缀合物
CA3057748A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
AU2018285562B2 (en) 2017-06-14 2024-01-18 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD19 ADC
RS62928B1 (sr) 2017-08-18 2022-03-31 Medimmune Ltd Konjugati pirolobenzodiazepina
IL273387B2 (en) 2017-09-20 2023-10-01 Ph Pharma Co Ltd Thylanstatin analogs
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CA3099920A1 (en) 2018-06-01 2019-12-05 Eisai R&D Management Co., Ltd. Splicing modulator antibody-drug conjugates and methods of use
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
EP3870235A1 (en) 2018-10-24 2021-09-01 F. Hoffmann-La Roche AG Conjugated chemical inducers of degradation and methods of use
JP2022513198A (ja) 2018-12-10 2022-02-07 ジェネンテック， インコーポレイテッド Ｆｃ含有タンパク質への部位特異的コンジュゲーションのための光架橋性ペプチド
JP2022512401A (ja) 2018-12-13 2022-02-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 ハーボキシジエンスプライシング調節薬抗体－薬物コンジュゲート及びその使用方法
US11702482B2 (en) 2018-12-17 2023-07-18 Revitope Limited Twin immune cell engager
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) * 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5780029A (en) 1989-11-14 1998-07-14 New York Medical College Antidiotypic monoclonal antibodies for treatment of melanoma
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5256643A (en) 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5264557A (en) 1991-08-23 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Polypeptide of a human cripto-related gene, CR-3
US6063379A (en) 1993-12-09 2000-05-16 Centro De Inmunologia Molecular Anti-idiotypic monoclonal antibodies and compositions including the anti-idiotypic monoclonal antibodies
US5981215A (en) * 1995-06-06 1999-11-09 Human Genome Sciences, Inc. Human criptin growth factor
EP0912738B1 (en) * 1996-05-22 2008-07-30 Viventia Biotech Inc. Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
AP1590A (en) 1998-12-23 2006-03-14 Pfizer Human monoclonal antibodies to CTLA-4.
US6335170B1 (en) * 1999-02-22 2002-01-01 Torben F. Orntoft Gene expression in bladder tumors
AU754808B2 (en) 1999-03-30 2002-11-28 Amgen Fremont Inc. Method for preparing Monoclonal Antibody
EP1179178A1 (en) * 1999-04-20 2002-02-13 William J. Kokolus Improved method of identifying and locating immunobiologically-active linear peptides
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
JP2001046066A (ja) 1999-08-03 2001-02-20 Kyowa Hakko Kogyo Co Ltd 新規な相補性決定領域を有するヒトｖｅｇｆ受容体ｋｄｒに対する抗体
DE60039448D1 (de) 1999-10-29 2008-08-21 Genentech Inc Gegen das prostata-stammzellantigen (psca) gerichtete antikörper und deren verwendung
US6663613B1 (en) 2000-01-25 2003-12-16 Bacchus Vascular, Inc. System and methods for clot dissolution
DE60134962D1 (de) * 2000-03-03 2008-09-04 Kyowa Hakko Kogyo Kk Anti-ccr4 antikörper und fragmente davon
US6333410B1 (en) * 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
GB0020953D0 (en) 2000-08-24 2000-10-11 Smithkline Beecham Biolog Vaccine
AU2001292724B2 (en) * 2000-09-18 2005-05-26 Biogen Idec Ma Inc. CRIPTO mutant and uses thereof
AU2002236871B2 (en) 2001-01-26 2006-09-28 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Detection and quantification of CRIPTO-1
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
MXPA03006771A (es) 2001-01-29 2004-05-05 Idec Pharma Corp Anticuerpos modificados y metodos de uso.
AUPR395801A0 (en) * 2001-03-26 2001-04-26 Austin Research Institute, The Antibodies against cancer
GEP20074091B (en) * 2001-04-26 2007-04-25 Biogen Idec Inc Cripto blocking antibodies and uses thereof
US7582299B2 (en) * 2001-04-26 2009-09-01 Biogen Idec Ma Inc. Cripto-specific antibodies
MXPA04002593A (es) * 2001-09-18 2004-05-31 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumor.
US20040014690A1 (en) * 2002-02-13 2004-01-22 Zhenkun Ma Macrolides with activity against methicillin-resistant staphylococcus aureus
JP2005520566A (ja) * 2002-03-22 2005-07-14 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｃｒｉｐｔｏ特異的抗体
ATE437950T1 (de) * 2003-09-15 2009-08-15 Res Dev Foundation Cripto-antagonismus von activin und tgf-b signalisierung
SG173313A1 (en) 2005-01-05 2011-08-29 Biogen Idec Inc Cripto binding molecules
WO2007127461A2 (en) * 2006-04-28 2007-11-08 Biogen Idec Ma Inc. Composition and methods for the detection of cripto-3

Also Published As

Publication number Publication date
EP1974749B1 (en) 2011-11-16
IS6999A (is) 2003-10-24
US20080166341A1 (en) 2008-07-10
JP4307845B2 (ja) 2009-08-05
US20120195912A1 (en) 2012-08-02
JP2004534020A (ja) 2004-11-11
RS51635B (sr) 2011-08-31
CN100352501C (zh) 2007-12-05
CN1606453A (zh) 2005-04-13
CZ20033208A3 (en) 2004-03-17
SI1390389T1 (sl) 2009-06-30
AR037223A1 (es) 2004-11-03
PT1390389E (pt) 2009-04-03
RS20110024A (en) 2011-08-31
WO2002088170A2 (en) 2002-11-07
ATE533508T1 (de) 2011-12-15
EE200300528A (et) 2004-08-16
US20100202962A1 (en) 2010-08-12
HK1058935A1 (en) 2004-06-11
SG157951A1 (en) 2010-01-29
US7888052B2 (en) 2011-02-15
EA200301158A1 (ru) 2005-06-30
ATE420659T1 (de) 2009-01-15
DK1390389T3 (da) 2009-04-20
EP1390389B1 (en) 2009-01-14
IS2662B (is) 2010-08-15
KR100592357B1 (ko) 2006-06-22
US7674462B2 (en) 2010-03-09
CA2443840C (en) 2010-10-26
SK14432003A3 (sk) 2004-07-07
CA2443840A1 (en) 2002-11-07
CA2715570A1 (en) 2002-11-07
US8673303B2 (en) 2014-03-18
US20090286265A1 (en) 2009-11-19
AR077759A2 (es) 2011-09-21
ES2321065T3 (es) 2009-06-02
HUP0501113A3 (en) 2007-12-28
US7531174B2 (en) 2009-05-12
MY150237A (en) 2013-12-31
YU84903A (sh) 2006-05-25
BG108363A (bg) 2004-09-30
EA007469B1 (ru) 2006-10-27
BR0209254A (pt) 2006-10-03
AR072554A2 (es) 2010-09-08
US20040146940A1 (en) 2004-07-29
JP2010163438A (ja) 2010-07-29
NZ566268A (en) 2009-09-25
KR20040028744A (ko) 2004-04-03
WO2002088170A3 (en) 2003-12-24
EP1974749A1 (en) 2008-10-01
CL2009002199A1 (es) 2010-05-07
JP2005314436A (ja) 2005-11-10
MY157382A (en) 2016-06-15
JP2009108100A (ja) 2009-05-21
DE60230868D1 (de) 2009-03-05
PL373513A1 (en) 2005-09-05
NO20034805L (no) 2003-12-23
CY1108960T1 (el) 2014-07-02
US20090285818A1 (en) 2009-11-19
EP1390389A4 (en) 2004-09-22
EP1390389A2 (en) 2004-02-25
EP2316486A3 (en) 2011-09-07
NO20034805D0 (no) 2003-10-27
EP2316486A2 (en) 2011-05-04
US8003763B2 (en) 2011-08-23
TR200301846T2 (tr) 2006-10-26
PL207087B1 (pl) 2010-10-29
GEP20074091B (en) 2007-04-25
MXPA03009797A (es) 2004-01-29
JP4575983B2 (ja) 2010-11-04

Similar Documents

Publication Publication Date Title
HK1058935A1 (en) Cripto blocking antibodies and uses thereof
EP1463742A4 (en) NEW PYRAZOLO AND PYRROLO PYRIMIDINES AND THEIR USES
EG23122A (en) Pyrrolcarboxamides and pyrrolcarbothioamides
EP1375518A4 (en) ANTIBODIES AGAINST OST OPONTINE, AND ITS USE
AU9667901A (en) Mycoattractants and mycopesticides
EP1425162A4 (en) OPTICAL MATERIALS AND OPTICAL DEVICES
AU2002244968A1 (en) Anti-osteopontin antibody and use thereof
TW510372U (en) Afforesting and landscaping device
EP1408978A4 (en) NOVEL PHENYLAMINO-PYRIMIDINES AND THEIR USE
IL154553A0 (en) Urocortin-iii and uses thereof
EP1414848A4 (en) REPLICINE PEPTIDES AND ITS USES
EP1419175A4 (en) PEPTIDES OF REPLIKIN AND THEIR USE
GB0126889D0 (en) Compounds and their uses
GB0114517D0 (en) Trx1 antibody and uses therefor
EP1408985A4 (en) NEW PYRIDOPYRIMIDONE AND ITS USES
EP1381061A4 (en) INDUCTANCE ELEMENT AND HOUSING
EP1367123A4 (en) NEUROTONIN AND ITS USE
ZA200308862B (en) Cripto blocking antibodies and uses thereof
EP1421101A4 (en) P-GLYCOPROTEINS AND THEIR USES
IL158573A0 (en) Cripto blocking antibodies and uses thereof
EP1437367A4 (en) ANTIBODIES AND ITS USE
GB0201256D0 (en) Magnotherapy device and use thereof
HK1072538A1 (en) Immunoregulatory antibodies and uses thereof
GB0200843D0 (en) Benzodioxinopyrroles their preparation and use
TW493609U (en) Moving and carrying device

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees